Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double attack on tough myeloma: stem cell transplant plus CAR-T cells

NCT ID NCT05632380

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study combines a stem cell transplant with a special immune cell therapy (C-CAR088) to treat people with ultra high-risk multiple myeloma, a blood cancer that is hard to treat. The 20 participants will receive their own stem cells after high-dose chemotherapy, followed by a single infusion of CAR-T cells that target the BCMA protein on myeloma cells. The goal is to see if this powerful combination is safe and can control the disease better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
C-CAR088 (a CAR-T cell therapy targeting BCMA) and autologous hematopoietic stem cell transplant
What this could lead to
If successful, this combination could offer a more effective treatment option for patients with ultra high-risk multiple myeloma who have limited alternatives.
What could go wrong
This is an early-phase trial with only 20 participants, so results may not apply broadly. There are risks of serious side effects from both the transplant and CAR-T therapy, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institute of Hematology & Blood Diseases Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300020, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.